Xellera Therapeutics Asia Limited

Novoheart develops products and provides services with a focus on engineering prototypes of bio-artificial human heart tissues and chambers for drug discovery, cardiotoxicity screening, disease modeling and future therapeutic applications.

Products and services include, but are not limited to, set-up and maintenance of proprietary physiological tissue systems that are supported by our in-house hardware (to measure physiological signals such as electrocardiograms, muscle contraction force, etc.) and software (to provide a user-friendly interface to display outputs and control the systems).

Overall, the unique technologies in Novoheart’s products and services have been designed to reduce the time, cost, use of animal models and increase human safety to facilitate pharmaceutical discovery and development. Novoheart is currently working with leading academic and pharmaceutical partners to innovate drug discovery and toxicity screening protocols.